drugset / Trial / NCT07609901
Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers
Phase 3
Not yet recruiting
372 enrolled
Radboud University Medical Center
Dutch National Health Care Institute · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation with no signs of disease.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2032-10-01
- Completion
- 2032-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | neopeptide-loaded dendritic cells | Cell therapy | — | Other |